Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Cardiff Oncology, Inc. (CRDF) had Return on Tangible Equity of -101.02% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.59M |
|
$-45.88M |
|
-- |
|
$0.59M |
|
$49.55M |
|
$-48.96M |
|
$3.11M |
|
$-45.85M |
|
$-45.85M |
|
$-45.85M |
|
$-45.85M |
|
$-45.85M |
|
$-45.85M |
|
$-48.96M |
|
$-49.44M |
|
66.84M |
|
66.84M |
|
$-0.69 |
|
$-0.69 |
|
| Balance Sheet Financials | |
$60.13M |
|
$0.58M |
|
$1.76M |
|
$61.88M |
|
$16.39M |
|
-- |
|
$0.10M |
|
$16.50M |
|
$45.39M |
|
$45.39M |
|
$45.39M |
|
68.31M |
|
| Cash Flow Statement Financials | |
$-37.92M |
|
$1.34M |
|
$2.58M |
|
$51.47M |
|
$17.47M |
|
$-34.00M |
|
$5.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.67 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-8256.32% |
|
-8256.32% |
|
-8337.94% |
|
-7732.04% |
|
-7736.26% |
|
$-37.97M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
3.26 |
|
112.02 |
|
-101.02% |
|
|
Return on Tangible Equity |
-101.02% |
-74.09% |
|
-101.02% |
|
$0.66 |
|
$-0.57 |
|
$-0.57 |
|